Excretion of cytosine arabinoside in saliva after its administration at high doses

Takehiko Mori, Rie Yamazaki, Tomonori Nakazato, Yoshinobu Aisa, Sawako Enoki, Masaaki Arai, Yasuo Ikeda, Shinichiro Okamoto

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

High-dose cytosine arabinoside (cytarabine) is widely used, either alone or in combination with other chemotherapeutic agents, for the treatment of refractory hematological malignancies. Its pharmacology in plasma and cerebrospinal fluid has been extensively examined. In this study, we measured the concentration of cytarabine in saliva of nine patients with hematological malignancies who received high-dose cytarabine. Cytarabine at a dose of 3 g/m was administered i.v. over 2 h. Saliva samples were collected before initiating cytarabine infusion, within 15 min after the completion of infusion and 2 or 4 h after infusion. The concentration of cytarabine was measured by HPLC methods. All nine patients showed a detectable level of cytarabine in saliva within 15 min after the completion of infusion (0.58±0.48 μg/ml), which was equivalent to 5% of its plasma concentration; however, the drug was no longer detectable in saliva thereafter. These findings suggest that cytarabine is excreted in saliva during and shortly after its administration at a high dose.

Original languageEnglish
Pages (from-to)597-598
Number of pages2
JournalAnti-Cancer Drugs
Volume17
Issue number5
Publication statusPublished - 2006 Jun

Fingerprint

Cytarabine
Saliva
Hematologic Neoplasms
Cerebrospinal Fluid
High Pressure Liquid Chromatography
Pharmacology
Pharmaceutical Preparations

Keywords

  • Cytarabine
  • Cytosine arabinoside
  • High dose
  • Saliva

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Excretion of cytosine arabinoside in saliva after its administration at high doses. / Mori, Takehiko; Yamazaki, Rie; Nakazato, Tomonori; Aisa, Yoshinobu; Enoki, Sawako; Arai, Masaaki; Ikeda, Yasuo; Okamoto, Shinichiro.

In: Anti-Cancer Drugs, Vol. 17, No. 5, 06.2006, p. 597-598.

Research output: Contribution to journalArticle

Mori, T, Yamazaki, R, Nakazato, T, Aisa, Y, Enoki, S, Arai, M, Ikeda, Y & Okamoto, S 2006, 'Excretion of cytosine arabinoside in saliva after its administration at high doses', Anti-Cancer Drugs, vol. 17, no. 5, pp. 597-598.
Mori, Takehiko ; Yamazaki, Rie ; Nakazato, Tomonori ; Aisa, Yoshinobu ; Enoki, Sawako ; Arai, Masaaki ; Ikeda, Yasuo ; Okamoto, Shinichiro. / Excretion of cytosine arabinoside in saliva after its administration at high doses. In: Anti-Cancer Drugs. 2006 ; Vol. 17, No. 5. pp. 597-598.
@article{0fb3b64571f14846bfd954c43d7fe94f,
title = "Excretion of cytosine arabinoside in saliva after its administration at high doses",
abstract = "High-dose cytosine arabinoside (cytarabine) is widely used, either alone or in combination with other chemotherapeutic agents, for the treatment of refractory hematological malignancies. Its pharmacology in plasma and cerebrospinal fluid has been extensively examined. In this study, we measured the concentration of cytarabine in saliva of nine patients with hematological malignancies who received high-dose cytarabine. Cytarabine at a dose of 3 g/m was administered i.v. over 2 h. Saliva samples were collected before initiating cytarabine infusion, within 15 min after the completion of infusion and 2 or 4 h after infusion. The concentration of cytarabine was measured by HPLC methods. All nine patients showed a detectable level of cytarabine in saliva within 15 min after the completion of infusion (0.58±0.48 μg/ml), which was equivalent to 5{\%} of its plasma concentration; however, the drug was no longer detectable in saliva thereafter. These findings suggest that cytarabine is excreted in saliva during and shortly after its administration at a high dose.",
keywords = "Cytarabine, Cytosine arabinoside, High dose, Saliva",
author = "Takehiko Mori and Rie Yamazaki and Tomonori Nakazato and Yoshinobu Aisa and Sawako Enoki and Masaaki Arai and Yasuo Ikeda and Shinichiro Okamoto",
year = "2006",
month = "6",
language = "English",
volume = "17",
pages = "597--598",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Excretion of cytosine arabinoside in saliva after its administration at high doses

AU - Mori, Takehiko

AU - Yamazaki, Rie

AU - Nakazato, Tomonori

AU - Aisa, Yoshinobu

AU - Enoki, Sawako

AU - Arai, Masaaki

AU - Ikeda, Yasuo

AU - Okamoto, Shinichiro

PY - 2006/6

Y1 - 2006/6

N2 - High-dose cytosine arabinoside (cytarabine) is widely used, either alone or in combination with other chemotherapeutic agents, for the treatment of refractory hematological malignancies. Its pharmacology in plasma and cerebrospinal fluid has been extensively examined. In this study, we measured the concentration of cytarabine in saliva of nine patients with hematological malignancies who received high-dose cytarabine. Cytarabine at a dose of 3 g/m was administered i.v. over 2 h. Saliva samples were collected before initiating cytarabine infusion, within 15 min after the completion of infusion and 2 or 4 h after infusion. The concentration of cytarabine was measured by HPLC methods. All nine patients showed a detectable level of cytarabine in saliva within 15 min after the completion of infusion (0.58±0.48 μg/ml), which was equivalent to 5% of its plasma concentration; however, the drug was no longer detectable in saliva thereafter. These findings suggest that cytarabine is excreted in saliva during and shortly after its administration at a high dose.

AB - High-dose cytosine arabinoside (cytarabine) is widely used, either alone or in combination with other chemotherapeutic agents, for the treatment of refractory hematological malignancies. Its pharmacology in plasma and cerebrospinal fluid has been extensively examined. In this study, we measured the concentration of cytarabine in saliva of nine patients with hematological malignancies who received high-dose cytarabine. Cytarabine at a dose of 3 g/m was administered i.v. over 2 h. Saliva samples were collected before initiating cytarabine infusion, within 15 min after the completion of infusion and 2 or 4 h after infusion. The concentration of cytarabine was measured by HPLC methods. All nine patients showed a detectable level of cytarabine in saliva within 15 min after the completion of infusion (0.58±0.48 μg/ml), which was equivalent to 5% of its plasma concentration; however, the drug was no longer detectable in saliva thereafter. These findings suggest that cytarabine is excreted in saliva during and shortly after its administration at a high dose.

KW - Cytarabine

KW - Cytosine arabinoside

KW - High dose

KW - Saliva

UR - http://www.scopus.com/inward/record.url?scp=33748136044&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748136044&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 597

EP - 598

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 5

ER -